Neuroendocrine carcinoma
Not recruitingStudy of daily low-dose temozolomide in patients with advanced neuroendocrine tumors (NETs) who are not eligible for standard treatments due to their health condition
Study of daily low-dose temozolomide in patients with advanced neuroendocrine tumors (NETs) who are not eligible for standard treatments due to their health condition
- Disease:Neuroendocrine carcinoma
- Substances:Temozolomide
Italy- Participants:18–64 years · 65+ years
- Substances:Temozolomide
- Sponsor:Istituto Europeo Di Oncologia S.r.l.


















